Patents Assigned to FATE THERAPEUTICS, INC.
-
Patent number: 11634688Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.Type: GrantFiled: February 4, 2020Date of Patent: April 25, 2023Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Raedun Clarke
-
Patent number: 11441126Abstract: The invention provides compositions and methods for manufacturing pluripotent cells. In particular, the invention provides improved culture platforms for manufacturing pluripotent cells with ground state pluripotency.Type: GrantFiled: October 14, 2016Date of Patent: September 13, 2022Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Megan Robinson, Ramzey Abujarour
-
Patent number: 11413309Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.Type: GrantFiled: January 20, 2017Date of Patent: August 16, 2022Assignee: FATE THERAPEUTICS, INC.Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta, Ian Hardy
-
Patent number: 11365394Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.Type: GrantFiled: February 19, 2021Date of Patent: June 21, 2022Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Ryan Bjordahl, Jode Goodridge, Tom Tong Lee
-
Patent number: 11352607Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.Type: GrantFiled: October 17, 2019Date of Patent: June 7, 2022Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
-
Patent number: 11268069Abstract: The invention provides compositions and methods for manufacturing pluripotent cells. In particular, the invention provides improved culture platforms for manufacturing pluripotent cells with ground state pluripotency. In various embodiments, the invention contemplates, in part, a composition comprising: (a) a Wnt pathway agonist; (b) a MEK inhibitor; and (c) a ROCK inhibitor. In certain embodiments, the composition further comprises bFGF or LIF.Type: GrantFiled: March 4, 2015Date of Patent: March 8, 2022Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Peter Flynn, Ramzey Abujarour, Megan Robinson
-
Patent number: 11162076Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.Type: GrantFiled: March 11, 2021Date of Patent: November 2, 2021Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Raedun Clarke, Ryan Bjordahl
-
Patent number: 11162075Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.Type: GrantFiled: October 2, 2020Date of Patent: November 2, 2021Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Raedun Clarke, Ryan Bjordahl
-
Patent number: 11135244Abstract: The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation.Type: GrantFiled: March 7, 2018Date of Patent: October 5, 2021Assignee: Fate Therapeutics, Inc.Inventor: Betsy Denise Rezner
-
Patent number: 11096964Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.Type: GrantFiled: January 20, 2017Date of Patent: August 24, 2021Assignee: FATE THERAPEUTICS, INC.Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
-
Patent number: 11072781Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.Type: GrantFiled: April 9, 2019Date of Patent: July 27, 2021Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
-
Patent number: 11052118Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.Type: GrantFiled: December 12, 2018Date of Patent: July 6, 2021Assignee: Fate Therapeutics, Inc.Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
-
Patent number: 10980838Abstract: The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.Type: GrantFiled: September 19, 2018Date of Patent: April 20, 2021Assignee: FATE THERAPEUTICS, INC.Inventors: Dan Shoemaker, Pratik S. Multani, John D. Mendlein, David Robbins
-
Patent number: 10954529Abstract: The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.Type: GrantFiled: June 13, 2018Date of Patent: March 23, 2021Assignee: FATE THERAPEUTICS, INC.Inventors: Peter Flynn, Bahram Valamehr
-
Patent number: 10947505Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.Type: GrantFiled: October 2, 2020Date of Patent: March 16, 2021Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Raedun Clarke, Ryan Bjordahl
-
Patent number: 10927346Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.Type: GrantFiled: September 19, 2019Date of Patent: February 23, 2021Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Ryan Bjordahl, Jode Goodridge, Tom Tong Lee
-
Patent number: 10858628Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.Type: GrantFiled: July 26, 2016Date of Patent: December 8, 2020Assignee: Fate Therapeutics, Inc.Inventors: Bahram Valamehr, Raedun Clarke, Ryan Bjordahl
-
Patent number: 10851412Abstract: The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.Type: GrantFiled: March 11, 2014Date of Patent: December 1, 2020Assignee: Fate Therapeutics, Inc.Inventors: Daniel Shoemaker, David L. Robbins
-
Patent number: 10844356Abstract: The invention provides cell culture conditions for culturing stem cells, including feeder-free conditions for generating and culturing human induced pluripotent stem cells (iPSCs). More particularly, the invention provides a culture platform that allows long-term culture of pluripotent cells in a feeder-free environment; reprogramming of cells in a feeder-free environment; single-cell dissociation of pluripotent cells; cell sorting of pluripotent cells; maintenance of an undifferentiated status; improved efficiency of reprogramming; and generation of a naïve pluripotent cell.Type: GrantFiled: June 30, 2017Date of Patent: November 24, 2020Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Ramzey Abujarour, Peter Flynn
-
Patent number: D998174Type: GrantFiled: April 21, 2020Date of Patent: September 5, 2023Assignee: FATE THERAPEUTICS, INC.Inventor: Gabriel Rodriguez